|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||0.9357 - 0.9700|
|52-week range||0.5350 - 1.7520|
|Beta (5Y monthly)||0.73|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2023 - 14 Aug 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
Adverum (ADVM) completes IND amendment with the FDA for initiating the phase II LUNA study on its gene therapy candidate, ADVM-022, for treating wet-age-related macular degeneration. Stock up.